A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer

Annals of Oncology

Volumn 13, Issue 6, 2002, Pages 874-882

  Sculier, J P ^a   Lafitte, J J ^a   Lecomte, J ^a   Berghmans, T ^a   Thiriaux, J ^a   Florin, M C ^a   Efremidis, A ^a   Alexopoulos, C G ^a   Recloux, P ^a   Ninane, V ^a   Mommen, P ^a   Paesmans, M ^a   Klastersky, J ^a   Vaslamatzis, M ^a   Koumakis, G ^a   Maetz, E ^a   Michel, J ^a   Giner Marco, V ^a   Berchier, M C ^a   Kroll, F ^a   Brohee D ^a   Zacharias, C ^a   Tagnon, A ^a   Richard, V ^a   Libert, P ^a   Richez, M ^a   Amourette, J ^a   Baumohl J ^a   Ficheroulle, X ^a   Watrigant, Y ^a   Crepin, J L ^a   Drowart, A ^a   Luce, S ^a   Line, M L ^a   Roboubi, R ^a   Bervar, J F ^a   more..

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Chemotherapy; Cisplatin; Gemcitabine; Ifosfamide; Non small cell lung cancer; Randomised trial

Indexed keywords

ANTIMETABOLITE; CARBOPLATIN; CISPLATIN; CYTARABINE; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GRANISETRON; IFOSFAMIDE; IRINOTECAN; MESNA; MITOMYCIN; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; PYRIMIDINE; TENIPOSIDE; VINBLASTINE; VINDESINE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART DISEASE; HUMAN; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUROLOGIC DISEASE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; AGED; BELGIUM; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; FOLLOW UP; LUNG TUMOR; MIDDLE AGED; MORTALITY; NEEDLE BIOPSY; PATHOLOGY; PROBABILITY; REFERENCE VALUE; REMISSION; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BELGIUM; BIOPSY, NEEDLE; CARCINOMA, NON-SMALL-CELL LUNG; COMPARATIVE STUDY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMAN; IFOSFAMIDE; LUNG NEOPLASMS; MALE; MIDDLE AGE; NEOPLASM STAGING; PROBABILITY; REFERENCE VALUES; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; HUMANS; MIDDLE AGED;

EID: 0035990063     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf154     Document Type: Article

References (28)

1. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
2. Best supportive care or chemotherapy for stage IV non-small-cell lung cancer
3. Chemotherapy of non-small-cell bronchial cancers. Meta-analysis of the literature as a function of the extent of the disease
4. Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party
5. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861
6. Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer
7. Chemotherapy of advanced non-small-cell lung cancer: A comparison of three active regimens
8. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life
9. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer
10. Phase II and III studies with new drugs for non-small-cell lung cancer: A systematic review of the literature with a methodology quality assessment
11. Single-agent gemcitabine versus cisplatin-etoposide: Early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer
12. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study
13. Cisplatin-carboplatin-gemcitabine or ifosfamide-gemcitabine in advanced non-small-cell lung carcinoma: Two pilot studies
14. A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party
15. Statistical tables for the design of clinical trials
16. Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party
17. The role of mitomycin in the treatment of non-small-cell lung cancer: A systematic review with meta-analysis of the literature
18. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: A multicentre randomised trial
19. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer
20. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer
21. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Group trial
22. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project
23. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomised multicentre trial
24. A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small-cell lung cancer (NSCLC)
25. Cisplatin/gemcitabine (CG) vs cisplatin/gemcitabine/vinorelbine (CGV) vs sequential doublets of gemcitabine/vinorelbine followed by ifosfamide/vinorelbine (GV/IV) in advanced non-small-cell lung cancer Lung Cancer Group phase III trial (GEPC/98-02)
26. A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5-fluorouracil: A regimen associated with major toxicity in patients with advanced non-small-cell lung cancer
27. Prognostic factors for survival in advanced non-small-cell lung cancer: Univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients. The European Lung Cancer Working Party
28. Evaluation of the TN sub-staging in patients with initially unresectable stage III non-small-cell lung cancer treated by induction chemotherapy